The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Immune-related adverse effect/toxicity
Publications
Late onset ipilimumab-induced pericarditis and pericardial effusion: a rare but life threatening complication.
Case reports in oncological medicine. 2015;2015:794842
Immune toxicities and long remission duration after ipilimumab therapy for metastatic melanoma: two illustrative cases.
Current oncology (Toronto, Ont.). 2013;20(2):e165-9
A severe case of ipilimumab-induced guillain-barré syndrome revealed by an occlusive enteric neuropathy: a differential diagnosis for ipilimumab-induced colitis.
Journal of immunotherapy (Hagerstown, Md. : 1997). 2013;36(1):77-8
Burst kinetics of sodium channels which lack fast inactivation in mouse neuroblastoma cells.
The Journal of physiology. 1987;392:563-85